H.R. 198 · 118th Congress
Drug Pricing Transparency and Accountability Act
- Stage
- In committee
- Sponsor
- Matthew Rosendale
- Introduced
- 2023-01-09
- Latest action
- 2024-12-17 · Referred to the Subcommittee on Health.
Summary
Drug Pricing Transparency and Accountability Act
This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.